- Seelos expects to release top-line data in two registrational studies in 2023
NEW YORK, May 15, 2023 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq:SEEL) ("Seelos"), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today provided a clinical update and reported its financial results for the first quarter ended March 31, 2023.
Read more at prnewswire.com